This case-control study aims to compare the efficacy, safety, and postoperative burden of MicroShunt versus trabeculectomy. The first consecutive cohort of MicroShunt procedures (n = 101) was matched to recent historical trabeculectomy procedures (n = 101) at two London hospital trusts. Primary endpoints included changes in intraocular pressure (IOP) and glaucoma medications. Secondary outcome measures included changes in retinal nerve fibre layer (RNFL) thickness, rates of complications, further theatre interventions, and the number of postoperative visits. From the baseline to Month-18, the median [interquartile range] IOP decreased from 22 [17-29] mmHg (on 4 [3-4] medications) to 15 [10-17] mmHg (on 0 [0-2] medications) and from 20 [16-28] mmHg (on 4 [3-4] medications) to 11 [10-13] mmHg (on 0 [0-0] medications) in the MicroShunt and trabeculectomy groups, respectively. IOP from Month-3 was significantly higher in the MicroShunt group ( = 0.006), with an increased number of medications from Month-12 ( = 0.024). There were greater RNFL thicknesses from Month-6 in the MicroShunt group ( = 0.005). The rates of complications were similar ( = 0.060) but with fewer interventions ( = 0.031) and postoperative visits ( = 0.001) in the MicroShunt group. Therefore, MicroShunt has inferior efficacy to trabeculectomy in lowering IOP and medications but provides a better safety profile and postoperative burden and may delay RNFL loss.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505905PMC
http://dx.doi.org/10.3390/jcm11185481DOI Listing

Publication Analysis

Top Keywords

microshunt group
12
microshunt
8
microshunt versus
8
versus trabeculectomy
8
postoperative burden
8
procedures 101
8
included changes
8
rates complications
8
postoperative visits
8
mmhg [3-4]
8

Similar Publications

Purpose: To investigate the efficacy and safety of the Preserflo MicroShunt (PMS) in treating glaucoma secondary to different uveitic glaucoma (UG) types in a European population.

Methods: This study evaluated consecutive eyes with UG that received the PMS. The primary outcome measure was 12-month surgical success (≥20% IOP reduction, target IOP of 6-21 mmHg).

View Article and Find Full Text PDF

Introduction: This study was performed to compare the efficacy and safety of PreserFlo MicroShunt (PMS) implantation with mitomycin C (MMC) applied by sub-tenon injection versus conventional application by MMC-soaked sponges.

Methods: This retrospective, 1-year cohort study included 100 eyes of 100 patients with glaucoma who underwent PMS implantation with MMC (0.4 mg/ml) delivered either by sub-tenon injection (50 eyes) or via soaked sponges (50 eyes).

View Article and Find Full Text PDF
Article Synopsis
  • This study aimed to assess the effectiveness and safety of a new surgical method called transconjunctival XEN® 45 gel stent implantation in treating primary open-angle glaucoma (POAG).
  • A total of 31 patients underwent the procedure, experiencing an average decrease in intraocular pressure from 25.3 mm Hg pre-surgery to 15.9 mm Hg post-surgery, with most not needing additional medications by the one-month follow-up.
  • The results suggest that this surgical technique is both safe and effective, offering a timely alternative for patients with POAG needing surgical intervention earlier in their treatment process.
View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted to evaluate the occurrence of hyphema (bleeding in the anterior chamber) after PRESERFLO MicroShunt surgery in glaucoma patients and its connection to the tube insertion position.
  • Out of 66 eyes reviewed, 23 experienced hyphema, equating to a 35% occurrence rate, with bleeding observed during surgery in 8 cases.
  • Despite the high frequency of hyphema, all cases resolved within weeks with stable intraocular pressure and visual acuity, highlighting the need to inform patients about this risk before surgery.
View Article and Find Full Text PDF

Early Results of PRESERFLO TM MicroShunt for Primary Open-angle Glaucoma in Caucasian Patients.

J Glaucoma

October 2024

Department of Ophthalmology, Medical Faculty Carl Gustav Carus, Technische Universität, Fetscherstrasse 74, 01307 Dresden, Germany.

Precis: The PRESERFLO MicroShunt effectively lowered intraocular pressure in primary high and normal pressure open-angle glaucoma.

Purpose: To evaluate the efficacy and safety of the PRESERFLOTM MicroShunt in patients with primary open-angle glaucoma (POAG) and the two variants high (HPG) and normal pressure glaucoma (NPG) after one year.

Methods: Single-center prospective interventional case series consecutively including eyes of White/European patients with POAG, who received the PRESERFLOTM MicroShunt as a primary and stand-alone glaucoma intervention.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!